DBV Technologies (DBVT) Other Non-Current Liabilities (2015 - 2025)
DBV Technologies (DBVT) posted Other Non-Current Liabilities of $8.4 million for Q3 2025, up 12.38% sequentially from $7.5 million in Q2 2025, and up 8.52% YoY from $7.8 million in Q3 2024.
DBV Technologies (DBVT) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
DBV Technologies has reported Other Non-Current Liabilities for 11 years, with the latest figure at $8.4 million in Q3 2025.
- Quarterly Other Non-Current Liabilities rose 8.52% year-over-year to $8.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $8.4 million (up 8.52% YoY) and the FY2024 annual result came in at $8.3 million, down 6.78% from the prior year.
- Other Non-Current Liabilities advanced to $8.4 million in Q3 2025 per DBVT's latest filing, from $7.5 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $17.0 million in Q3 2021 and troughed at $1.3 million in Q1 2021.
- A 5-year average of $8.1 million and a median of $8.3 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2024: Other Non-Current Liabilities surged 1766.31% in 2021, then sank 55.0% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $2.1 million in 2021, then soared by 120.54% to $4.7 million in 2022, then soared by 88.68% to $8.9 million in 2023, then slipped by 6.78% to $8.3 million in 2024, then gained by 1.45% to $8.4 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $8.4 million, $7.5 million, and $5.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 8.33 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Jun 30, 2024 | 6.16 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 11.37 Mn |
| Jun 30, 2023 | 11.25 Mn |
| Mar 31, 2023 | 11.16 Mn |
| Dec 31, 2022 | 4.74 Mn |
| Sep 30, 2022 | 9.59 Mn |
| Jun 30, 2022 | 10.54 Mn |
| Mar 31, 2022 | 1.46 Mn |
| Dec 31, 2021 | 2.15 Mn |
| Sep 30, 2021 | 16.95 Mn |
| Jun 30, 2021 | 16.14 Mn |
| Mar 31, 2021 | 1.29 Mn |
| Dec 31, 2020 | 475,000.00 |